This trial enrolled 25 malignant pleural mesothelioma patients, 1 breast cancer patient, and 1 NSCLC patient and provided intrapleural administration of mesothelin-targeted chimeric antigen receptor (CAR) T cell therapy, which was shown to be safe and tolerable [59]. Here, MSLN is linked to malignant pleural mesothelioma.